AstraZeneca Sues Mylan Over Planned Vimovo Generic

Law360, New York (July 1, 2013, 2:12 PM EDT) -- AstraZeneca AB and Pozen Inc. on Friday sued Mylan Pharmaceuticals Inc. in New Jersey federal court, alleging the generic-drug maker had infringed on seven patents with its planned generic version of arthritis treatment Vimovo.

According to AZ, Mylan's planned generic versions of delayed-release combination naproxen and esomeprazole magnesium infringes on six patents that it owns — U.S. Patent Numbers 5,714,504; 6,369,085; 6,875,872; 7,411,070; 7,745,466; and 5,948,789— as well as U.S Patent Number 6,926,907, licensed to AZ by Pozen.

"The products, if approved, will be administered to...
To view the full article, register now.